Kyverna Therapeutics (KYTX) Free Cash Flow (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Free Cash Flow data on file, last reported at -$41.6 million in Q1 2026.

• Quarterly Free Cash Flow rose 8.4% year-over-year to -$41.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$151.0 million (down 11.04% YoY) and the FY2025 annual result came in at -$154.8 million, down 33.24% from the prior year.
• Free Cash Flow slipped to -$41.6 million in Q1 2026, from -$34.6 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$11.1 million in Q2 2023 to a low of -$45.4 million in Q1 2025.
• A 4-year average of -$28.2 million and a median of -$28.5 million in 2024 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2024 — Free Cash Flow slumped 146.51% — and 2025, when it gained 8.9%.
• Tracing KYTX's Free Cash Flow over 4 years: stood at -$20.1 million in 2023, then slumped by 88.92% to -$38.0 million in 2024, then climbed by 8.9% to -$34.6 million in 2025, then retreated by 20.11% to -$41.6 million in 2026.
• The last three Free Cash Flow figures came in at -$41.6 million (Q1 2026), -$34.6 million (Q4 2025), and -$42.8 million (Q3 2025), per Business Quant data.